Pancreatic Cancer Research

ResearcherKorea UniversityActive in the last 2 years

Kwangmeyung Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7919-188X; OpenAlex author ID A5055447223. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 3

  1. Cancer-Specific and Pro-Apoptotic PEGylated Liposomes Containing SMAC-Mimetic Doxorubicin Prodrug for Safe High-Dose Delivery in Pancreatic Cancer. Last author DOI 10.1002/adhm.202502018↗
  2. Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. Co-author DOI 10.1016/j.jconrel.2024.10.070↗
  3. Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer. Last author DOI 10.3390/molecules27082529↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eunsung Jun · 1 shared paper, 2025 · strength 0.27
  2. Inki Kim · 1 shared paper, 2025 · strength 0.27
  3. Ji Hye Jeong · 1 shared paper, 2025 · strength 0.27
  4. Yeonjin Kim · 1 shared paper, 2025 · strength 0.27
  5. Young Seok Cho · 1 shared paper, 2024 · strength 0.21
  6. Youngro Byun · 1 shared paper, 2024 · strength 0.21
  7. In Kyung Cho · 1 shared paper, 2022 · strength 0.20
  8. Jong-Ho Kim · 1 shared paper, 2022 · strength 0.20
  9. Wooram Um · 1 shared paper, 2022 · strength 0.20
  10. Man Kyu Shim · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.